Pharmaceutical firms urged to focus on development of new drug entities

Published: 2004-06-24 07:00:00

Updated: 2004-06-24 07:00:00

Business sources say that as Ranbaxy Labs in India has been recognized as the world's generic marker with last year's sales of over 1 trillion won, domestic pharmaceutical firms need to give priority to new drug entities as part of efforts to nurture their global competitiveness, since these enti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK